Chronic Myeloid Leukaemia : A paradigm for malignancy or just a strange disease? by McCann, Shaun R.
Sultan Qaboos University Med J, November 2012, Vol. 12, Iss. 4, pp. 422-428, Epub. 20th Nov 12 
Submitted 1st Mar 12
Revision Req. 1st May 12, Revision recd. 28th May 12
Accepted 4th Jul 12
Chronic myeloid leukaemia (CML) was first described as a distinct entity in 1845. J.H. Bennett described a young man 
who died with an enormously enlarged spleen, 
and D. Craigie published a case of disease of the 
spleen, in which death took place as a consequence 
of the presence of purulent matter in the blood.1,2 
Both of these cases were published in Edinburgh. 
According to Barnett and Eaves, a further case 
was described in 1845 by R. Virchow.3,4 However 
what makes CML such an interesting disease is 
that it is the first human cancer to be associated 
with a non-random chromosomal abnormality, 
the Philadelphia chromosome.5,6 Nowell and 
Hungerford described the relatively small 
chromosome 22, which is present in all cases of 
CML. This was extremely important because, for 
the first time in humans, doctors and scientists 
were able to communicate with one another 
about a disease which had a specific chromosomal 
marker; in other words, there was a well-defined 
chromosomal marker which defined the disease. 
االبيضاض النخاعي املزمن
منوذج لورم خبيث أو جمرد مرض غريب؟
�صون مكان
امللخ�ص: حتول االبيضاض النخاعي املزمن من مرض مميت إىل مرض ميكن التعامل معه باألدوية عن طريق الفم. بدأ وصف املرض ألول مرة يف منتصف 
القرن 19، ومل يكن هناك أي عالج مقبول على نطاق واسع حىت ظهور زرع اخلاليا اجلذعية يف أواخر السبعينيات، وكان هذا العالج ذي قيمة حمدودة 
بسبب املشاكل الناجتة عن قلة املتربعني والُسّمية. لكن بعد اكتشاف صبغي فيالدلفيا وبعد معرفة مسؤولية النمط الظاهري للمرض اخلبيث من قبل املوّرث 
) chimaeric ABL / BCR( فُتحت األبواب لطرق عالجية أخرى هلذا املرض. تغريت حياة املرضى املصابني هبذا املرض بعد تطوير مثبطات 
أنزمي كاينيز التايروسني. وكان العالج ناجحا جدا مع العديد من املرضى يف َهْدأَة املرض السريرية واجلزيئية ألكثر من 10 سنوات، بعدها أصبح االمتثال 
للعالج مشكلة يف الوقت احلايل. تتجه املناقشات يف الوقت الراهن حنو االستخدام احملتمل للجيل الثاين ملثبطات أنزمي كاينيز التايروسني للمرضى الذين 
شخصوا حديثا لتجنب التكلفة العالية هلذه األدوية. وعلى الرغم من جناح مثبطات أنزمي كاينيز التايروسني يف عالج االبيضاض النخاعي املزمن ، مل تتحقق 
مثل هذه النتائج الناجحة يف عالج حاالت السرطان الشائعة، وبالتايل يطرح السؤال اآليت: هل يُعّد االبيضاض النخاعي املزمن منوذجا للخبث أو ُهَو جمّرد 
مرض غريب؟
مفتاح الكلمات: االبي�صا�ض النخاعي املزمن، �صبغي فيالدلفيا، مثبطات انزمي كاينيز التايرو�صني.
abstract: Chronic myeloid leukaemia (CML), previously a fatal illness, is now readily manageable with oral 
medication. First described in the 1840s, there was no widely accepted cure until the advent of allogeneic stem 
cell transplantation in the late 1970s. This treatment was of limited value because of donor availability and toxicity 
problems. Discovering the Philadelphia chromosome and demonstrating that the BCR-ABL chimaeric gene was 
responsible for the malignant phenotype opened new avenues. The development of tyrosine kinase inhibitors 
(TKIs) changed the lives of patients with CML. The treatment has been so successful that compliance is now 
a problem. Currently under discussion is the possible use of more expensive second generation TKIs for newly 
diagnosed patients. In spite of the success with TKIs, treatment of common cancers has not been so successful. Is 
CML therefore a paradigm for malignancy or just a strange disease?
Keywords:  Chronic myeloid leukaemia; Philadelphia chromosome; Tyrosine kinase inhibitor.
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production of a P210 protein in 95% of patients 
and a P190 in the remaining 5%. This should be 
established at diagnosis as it may be used to measure 
response to treatment. This hybrid gene expresses 
a tyrosine kinase (TK) that is constitutively active 
and influences adhesion of cells to the bone marrow 
stroma and cell division, and probably most 
importantly it inhibits apoptosis. These experiments 
were seminal because they raised the possibility of a 
completely new approach to treatment.
From the 1970s to the 1990s, there was no 
adequate chemotherapy for CML, although 
prognostic scores were developed.9,10 The average 
life expectancy was about three years and death 
was usually a result of accelerated disease, or a 
‘blast crisis’. Most patients were diagnosed in the 
first chronic phase (CP) but the disease inevitably 
progressed to an accelerated phase and blast crisis, 
simulating acute leukaemia and death. A blast crisis 
was initially thought to be a form of acute myeloid 
leukaemia, but the description by Marks et al. of the 
presence of the enzyme terminal deoxynucleotidyl 
transferase (TdT) in the cells of some patients 
clearly showed that the acute leukaemic phase 
could be lymphoid or myeloid.11 Treatment of 
1CP consisted of busulfan, hydroxycarbamide, or 
recombinant interferon-α. The former two drugs 
reduced the white cell count and had some impact 
on symptoms but did little to halt the inexorable 
Improvements in 
Technology increased 
our Understanding of the 
Pathogenesis of CML
The exploitation of discoveries is often limited 
by lack of technology. Likewise with CML, it was 
not until the introduction of banding technology 
that Rowley demonstrated that the Philadelphia 
chromosome, instead of a small chromosome 22, 
was in fact a reciprocal translocation between a part 
of the long arm of chromosome 9 and the long arm 
of chromosome 22 [Figure 1].7 Current diagnostic 
methods include fluorescent in situ hybridisation 
(FISH). 
Interesting as these findings may have been to 
scientists, the real question for medical doctors 
was, ‘Could these observations be the key to 
new treatments?’ To put it another way, was the 
reciprocal translocation an epiphenomenon or was 
the genetic abnormality the cause of the malignant 
phenotype? It took some time but eventually a 
number of scientists demonstrated that this was 
indeed the case. Using animal models, Daley, 
among others, clearly demonstrated that the 
malignant phenotype was caused by the BCR-ABL 
hybrid gene on chromosome 22.8 The fusion of the 
3’ segment of ABL1 to the 5’ part of the BCR gene 
resulting in BCR-ABL1 transcripts gave rise to the 
 
Figure 1: A karyotype showing the Philadelphia chromosome.
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the patients were that the drug was available in an 
oral form and was relatively free of severe toxicity. 
This drug launched the term ‘targeted therapy’ into 
medicine. Imatinib is a specific inhibitor of the 
TK domain in the ABL gene (Abelson is a proto-
oncogene), c-kit, and platelet-derived growth factor 
receptor (PDGFR). TKs have an active binding site 
for adenosine 5'-triphosphate (ATP), which leads 
to phosphorylation of many intracellular substrates 
[Figure 2]. Glivec® binds close to the ATP binding 
site and inhibits the enzyme activity. Inhibition of 
BCR-ABL by Glivec® also stimulates its transfer into 
the cell nucleus where it ceases to act as an anti-
apoptotic agent.17 The drug is metabolised by the liver 
enzyme CYP34A. Toxicity is minimal and consists 
of anaemia (probably secondary to inhibition of the 
c-kit), thrombocytopaenia, musculoskeletal pain, 
and skin rashes. Most patients respond to a single 
daily dose of 400 mg. 
The best-known data demonstrating the 
efficacy of imatinib come from the International 
Randomized Study of Interferon and STI571. A seven 
year follow-up showed a rate of event-free survival 
(EFS) of 83% and, most importantly, freedom of 
progression to a blast crisis in 92%. Patients who 
achieved a complete cytogenetic response (CCyR) 
at 12 months were less likely to progress to an 
advanced stage or a blast crisis (97%). Thus, there 
was a high cytogenetic response rate and that was 
progress of the disease. There was no effect on the 
underlying chromosomal abnormality. Interferon-α 
was accompanied by significant toxicity but was 
occasionally associated with the disappearance of 
the Philadelphia chromosome.12 Progression of 
the disease was associated with genetic instability 
manifest by +8, +Ph, +19 and i(17q). The only 
curative therapy before the introduction of TK 
inhibitors (TKIs) was allogeneic stem cell (mostly 
bone marrow) transplantation. A number of limiting 
factors, however, dictated the success of allografting: 
the availability of a matched sibling donor, expense, 
and access to an experienced transplant unit.13 The 
toxicity of stem cell transplantation is considerable 
and includes sterility.14 As the median age for 
presentation of CML is between 50 and 60 years 
(depending on the reference), allogeneic stem 
cell transplantation was not an option for older 
patients when classical myeloablative conditioning 
was used. However, despite these limitations, if 
allogeneic stem cell transplantation was carried out 
in the first chronic phase within a year of diagnosis, 
the survival rate was excellent.15 
The world changed forever with the use of TKIs 
and the initial publications by Druker et al.16 The 
first drug that had significant activity against the 
chromosomal lesion in CML was a TKI known 
initially as ST-571 (imatinib mesylate) and marketed 
by Novartis as Glivec®. The important issues for 
 
Figure 2: The mechanism of action of tyrosine kinase inhibitors.
Figure reproduced with the kind permission of Professor Junia Melo, Head of Leukaemia Research, Division of Haematology, Centre for Cancer 
Biology, IMVS Pathology, Adeliade, Australia.
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seem strange that a relatively non-toxic oral drug 
which produces a dramatic effect in most patients 
would be associated with this problem. Indeed, we 
know that patients on chronic medication for non-
malignant diseases have <50% compliance after 5 
years. The incidence may not be as high in CML, 
but compliance is a problem. The measurement of 
plasma levels of imatinib was initially believed to 
overcome this problem as trough levels were shown 
to be associated with the degree of response.22 
Recent studies from the Hammersmith Hospital 
in the UK have shown that patients may fail to 
comply but take an extra dose the day before 
coming to the clinic, thus making plasma levels 
an unreliable indicator of compliance.23 Continual 
reinforcement of patients with encouragement 
to take the drug together with a warning of the 
potential consequences of intermittent therapy 
should be given. It should also be noted that in a 
5-year follow-up, 25% of newly diagnosed patients 
had discontinued imatinib because of failure to 
respond, or toxicity.24
Another perhaps more serious cause of failure 
to respond to imatinib or loss of response may 
be due to mutations in the BCR-ABL kinase 
domain (ABL1 KD mutations). Techniques 
to detect these mutations include direct 
sequencing, denaturing high-performance liquid 
associated with failure of progression of the disease.18 
As well as documenting a cytogenetic response to 
imatinib, we are now able to apply the most modern 
technology to monitor patient response using a 
multiplex polymerase chain reaction (PCR).19 A 
three-log reduction in the number of transcripts is 
now taken as evidence reflecting an optimal patient 
response. The European LeukemiaNet (ELN) has 
published criteria for an optimal response to Glivec® 
and recommendations for other therapies.20 
Although the outlook has changed dramatically 
for patients with CML since the advent of imatinib, 
not all patients respond to this drug, and some 
patients who respond initially subsequently lose 
their response. These observations stimulated the 
development of more potent, second generation 
TKIs. These drugs are more potent than imatinib, 
more expensive, and have greater toxicity. However, 
Druker still gives imatinib to all new patients with 
CML as an initial therapy.21 So what is the ideal 
response to Glivec and who should receive second 
generation TKIs? The ELN recommendations for 
an optimal response include a complete cytogenetic 
response at 12 months and a major molecular 
response at 18 months.  
What should the doctor do if these milestones 
are not reached? One of the interesting new 
findings has been poor patient compliance. It may 
 
Figure 3: The decrease in numbers of patients referred for allogeneic transplantation.
Figure reproduced with the kind permission of  the Center for International Blood and Marrow Transplant Research. www.cibmtr.org
AML = Acute Myeloid Leukaemia; ALL = Acute Lymphoblastic Leukaemia; CML = Chronic Myeloid Leukaemia; AA = Aplastic Anaemia; Lym 
= Lymphoma; MM = Multiple Myeloma; CLL = Chronic Lymphoblastic Leukaemia.
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allografting, which include chronic graft-versus-
host disease (GVHD) and death, far outweigh the 
risks of taking TKIs, but the expense of taking TKIs 
indefinitely may be prohibitive in some countries. It 
should also be remembered that relapse can occur 
many years after apparently successful allografting. 
It is clear that imatinib or other TKIs have a role 
to play in such circumstances.34,35 Perhaps patients 
under 25 years of age in CP1 with a fully matched 
sibling donor should be referred for allografting, 
but even this is controversial as fatal GVHD may 
occur in this setting.  
In the last 10 years, CML has gone from the 
most common indication for allogeneic stem cell 
transplantation to the least common because of 
the use of effective treatment with TKIs. Whether 
newly diagnosed patients should be given imatinib 
or a second-generation TKI as initial therapy 
remains controversial. Patients who relapse or do 
not respond to TKIs should be investigated for 
compliance and/or ABL-KD mutations. Although 
second-generation TKIs may play some role in 
the treatment of advanced disease or blast crisis 
(not discussed here), these clinical entities remain 
problematical and, if feasible, such patients 
should be referred for allogeneic transplantation. 
As mentioned by Druker, one of the benefits of 
imatinib is that it reduces the chances of a patient 
progressing to blast crisis and thus makes it difficult 
to define optimal treatment for advanced disease.21
The fact that TKIs may not cure CML but 
achieve a remission during which the disease 
remains undetectable at a molecular level seems 
a philosophical question that is not important for 
most patients. After all, most diseases, with the 
exception of infections, remain incurable, but 
many are treatable. For patients leading a virtually 
normal life 13 years after the initial diagnosis of 
CML, and taking TKI medication orally, the issue 
of undetectable molecular disease may seem 
somewhat irrelevant. 
Unfortunately, the success of the TKIs has not 
been matched in common cancers such as that 
of the breast, bowel, or prostate so the question 
remains to be answered: ‘Is CML a paradigm for 
malignancy, or just a strange disease?’
note
The author wishes to declare that the opinions 
expressed in this article are his own and do not 
chromatography, pyrosequencing, and allele-
specific PCR; however, direct sequencing is the 
recommended technique.25,26 In some cases, the 
detection of a specific ABL1 KD mutation will 
indicate appropriate therapy, whereas many 
mutations do not carry any prognostic significance. 
The presence of the T315I mutation is important, 
as patients with this ABL1 KD mutation will 
not respond to any of the second generation 
TKIs, although there is emerging evidence of 
possible response to an aurora kinase inhibitor, 
ponatinib.27–29 If a patient has a suitable donor, 
s/he should be referred for allogeneic stem cell 
transplantation. Some mutations are more likely to 
respond to second line TKIs. ABL1 KD mutations 
E25K/V, F359C/V, and Y253H seem sensitive to 
dasatinib, a second generation TKI, whereas F317L 
and V299L respond to nitolinib.30
There are other mechanisms of resistance to 
imatinib not discussed here, including OCT1 
activity and multiple copies of the Ph chromosome. 
Multidrug resistance polymorphisms may also 
play a role. In a significant number of patients, the 
mechanism of resistance to TKIs is still unknown.  
What is the place of second-generation TKIs? 
This is controversial at present.31 Two recent reports 
in the New England Journal of Medicine pointed 
out the efficacy of these agents.32,33 They both are 
associated with more rapid and deeper responses 
than imatinib, but toxicity is increased. Some 
investigators claim that second-generation TKIs 
should be used, therefore, for all newly diagnosed 
patients but, as mentioned earlier, Druker still 
initiates therapy with imatnib in newly diagnosed 
patients. The other issue which has become and 
will be of increasing significance is cost. At present, 
imatinib costs €30,000 (c. $38,400) per patient per 
annum and the second-generation drugs are more 
expensive. As all of these drugs significantly delay 
the progression of CML, there will be increasing 
numbers of patients in 1CP. Can patients with 
a three-log molecular response, which has been 
maintained for a number of years, discontinue 
therapy? Unfortunately, the answer is not simple. A 
number of studies are currently examining this issue 
but, at present, patients are advised to continue 
TKIs indefinitely.
What is the current role of allografting? Referring 
patients for allografting is certainly less frequent than 
10 years ago [Figure 3]. The risks associated with 
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